of robust, long-lasting protective immune responses. 6 At week 60, the MERS DNA vaccine induced humoral and cellular responses in only 51 (77%) of 66 participants and 42 (64%) of 66 participants, respectively, and only two (3%) of 66 participants maintained neutralising antibodies until the end of the study. Thus, generation of humoral and cellular immune responses might not equate with long-term protection.
The phase 1 DNA vaccine developed for the US military aptly illustrates that advances in technology, vaccine platforms, clinical trial designs, and bioinformatics, together with serious investment by stakeholders, provide opportunities for rapid vaccine development and evaluation. Countries where MERS is endemic must invest more seriously in both human and camel vaccine development. With the continuing outbreaks of MERS coronavirus 7 years after it was first discovered, effective human vaccines could be the ideal way to prevent spread and evolution of the virus. Logistical issues of the small and sporadic number of new MERS cases at different geographical locations need to be overcome by a more coordinated approach for research, something that needs to be advanced more rapidly than the current pace of research and development. 7 Being a DNA vaccine candidate, the GLS-5300 MERS coronavirus vaccine allowed for rapid design and production and was advanced into the clinic within 9 months of preclinical candidate vaccine selection. The encouraging results of the phase 1 MERS DNA vaccine study 1 should be advanced quickly to include studies with adequate numbers of elderly and comorbid populations, with careful consideration of safety and of the longevity of the protective response, thereby mitigating future outbreaks and alleviating disease burden from the most susceptible populationselderly people, immunosuppressed people, and health-care workers. are too big to study in most biosafety facilities. These limitations restrict vaccination tests in camels. It is increasingly recognised that a One Health approach is needed for effective investigation, prevention, and control of emerging zoonotic diseases. In the context of emerging zoonoses, human and veterinary medicines must work together. The eradication of MERS coronavirus in dromedary camels is the primary condition for the control of this disease in the Arabian Peninsula. If the virus continues to circulate in camels, it might attain new mutations that enable human-to-human transmission, resulting in the generation of superspreader strains. A comprehensive MERS prevention and control effort should focus not only on a human vaccine but also on camel vaccination.
We declare no competing interests. 3 advancement of this DNA vaccine to a second phase 1 or 2a trial will need to overcome other operational and logistical challenges and must target those most at risk of succumbing to the disease. The high mortality and severe disease seen in MERS are positively correlated with age and presence of comorbidities, including chronic liver, kidney, and heart disease, diabetes, and immunosuppressive conditions. 4 Furthermore, host immune responses to MERS coronavirus could contribute to disease severity and outcomes. Thus, vaccine-induced immune responses in populations with these high-risk characteristics could potentially have harmful effects. These barriers were encountered in severe acute respiratory syndrome coronavirus vaccine development over 15 years ago, and might also hold true for MERS coronavirus. 5 Therefore, any MERS coronavirus vaccine must specifically target the most vulnerable populations and assess safety and generation liver failure, 2 thus suggesting that, apart from high viral load, severe paracetamol-induced liver injury could be an important cofactor of liver failure in patients with yellow fever and their 36% fatality rate. 1 Paracetamol was reported as a cofactor of acute liver failure due to hepatotropic viruses A, B, and E. Accordingly, the following therapeutic recommendations could be proposed for improving the survival of symptomatic patients suspected to have yellow fever: cessation of paracetamol administration and early intravenous administration of N-acetylcysteine, the antidote to paracetamol hepatotoxicity, in patients with an international normalised ratio greater than 1·5, and also in patients in whom recent paracetamol ingestion is denied or absent. 2 Early administration of N-acetylcysteine was associated with a high survival rate in two independent, uncontrolled, short case series of patients with dengue fever-another arboviral infection-and early acute liver failure. 3, 4 
